koto_feja/E+ via Getty Images
- BeOne Medicines (OTCPK:BEIGF) has received breakthrough therapy designation from the U.S. FDA for sonrotoclax, a treatment aimed at adult patients suffering from relapsed or refractory mantle cell lymphoma.
- In addition, the FDA has approved BeOne’s involvement in Project Orbis, a global initiative